News & Events

Read about our latest product developments and partnerships, industry advances and events.

Accera, Inc. Introduces Axona® Patient Starter Kits for Alzheimer's Disease Patients Beginning Therapy

March 1, 2013

Kits Ensure Proper Titration and Make It Easier Than Ever to Start and Stay on Therapy

Broomfield, CO, February 28, 2013 – Accera, Inc., a privately-held, commercial-stage, healthcare company focused on the discovery and development of innovative clinical applications to address acute and chronic neurodegenerative diseases, announced today the launch of its Axona® Patient Starter Kits for patients with mild-to-moderate Alzheimer's disease (AD) beginning Axona. Accera's Axona Patient Starter Kits have an innovative new design and provide everything needed for the first week of therapy. The kits make titration simple and help improve tolerability by gradually acclimating patients to Axona.

Axona is a specially formulated, prescription-only medical food intended for the clinical dietary management of the metabolic processes associated with mild-to-moderate AD. It is the first proprietary commercialized AD therapy that addresses diminished cerebral glucose metabolism (DCGM), a key underlying pathology of AD. In AD, the brain's ability to metabolize glucose is significantly diminished, leaving a large portion of its energy needs unfulfilled. Axona works by providing ketones as an alternative fuel source for brain cells. Ketones can help supply up to 60% of the brain's energy needs. In clinical trials, Axona has been shown to induce safe, therapeutic, tolerable and predictable levels of ketosis that enhance memory in patients with mild-to-moderate AD.

Each dose of Axona contains medium chain triglycerides (MCTs) that when ingested produce ketones. Some patients may experience mild gastrointestinal (GI) problems if MCTs are rapidly ingested. However, it's simple to reduce these effects by titrating Axona during the first week on therapy.

"The new Axona Patient Starter Kits are a great way to help patients successfully acclimate to Axona during their first week of therapy," said Richard Isaacson, M.D., Associate Professor of Clinical Neurology, Vice Chair of Education and Education Director of the McKnight Brain Institute in the Department of Neurology at the University of Miami (UM) Miller School of Medicine. "The individual compartments in Accera's Axona Patient Starter Kits contain individual dosing for each day and make it simple for caregivers or patients to gradually work their way to the full recommended dose."

For more information on Axona, visit www.about-axona.com, or call 1-877-649-0004.

BacktoTop